Trusted Resources: News & Meetings
Latest announcements and gatherings
Teprotumumab for Treatment of Thyroid Eye Disease Meets Endpoints in Phase 3 Study
Results from the phase 3 OPTIC study showed more patients treated with teprotumumab had a meaningful improvement in proptosis compared with those who received placebo.
The confirmatory trial evaluated teprotumumab for the treatment of active thyroid eye disease.
The primary endpoint of the study was met, with 82.9% of 41 teprotumumab-treated patients achieving a 2 mm or more reduction of proptosis compared with 9.5% of 42 placebo patients, a statically significant difference (P < .001), according to a press release from Horizon Pharma.
All secondary endpoints were met in the study. A greater percentage of teprotumumab-treated patients experienced a 2 point or greater reduction in clinical activity score and a 2 mm or greater reduction in proptosis from baseline, with no deterioration in clinical activity score or proptosis in the fellow eye, compared with the placebo group.
myBinderRelated Content
-
Quality of life assessment in thyroid eye disease: Tess Fayershttps://www.youtube.com/watch?v=zECaq87R...
-
Randomized Controlled Trial of Rituximab in Patients With Graves’ OrbitopathyContext: Graves' orbitopathy (GO) is a ...
-
Predictive Score for the Development or Progression of Graves’ Orbitopathy in Patients With Newly Diagnosed Gr...Objective: To construct a predictive sc...
-
A New Era in the Treatment of Thyroid Eye DiseasePurpose: Improved understanding of thyr...
-
Ask a Doctor questions about Graves’ disease, thyroid eye disease, & Hashimoto’s thyroiditishttps://www.youtube.com/watch?v=RxElrnS6...
-
Patient Story – Thyroid Eye Diseasehttps://www.youtube.com/watch?v=GnXbXSah...
-
TED Is Separate and Distinct From Graves ’ Disease, and Requires Different TreatmentTED is a heterogeneous condition, meanin...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google